THE HAGUE: The EU’s medicines regulator said on Wednesday that blood clots should be listed as a rare side effect of the AstraZeneca vaccine but the benefits of the jab continue to outweigh risks, as several countries battle fresh virus surges amid vaccine shortfalls.
A number of nations have suspended the use of AstraZeneca’s vaccine for younger populations after it was earlier banned outright in several places over blood clot scares among younger people.
The back-and-forth over the shot comes as countries from Germany to Ukraine and India face new waves of infections and deaths from the virus that has now killed more than 2.8 million people globally.
Governments are scrambling to secure much-needed vaccine doses, with Australia the latest nation to complain of shortages that it blamed on EU export controls.
The European Medicines Agency (EMA) said Wednesday that blood clots were a “very rare” risk, encouraging countries to continue its use.
“EMA’s safety committee has concluded today that unusual blood clots with low blood platelets should be listed as very rare side effects” of the shot, the agency said in a statement.
The announcement came after its safety committee examined reports of blood clots, but EMA chief Emer Cooke said no particular risk factor had been identified but the clots could be linked to an immune response to the vaccine.
“Specific risk factors such as age, gender or medical history have not been able to be confirmed, as the rare events are seen in all ages,” she told a news conference.
“The benefits of the AstraZeneca vaccine in preventing Covid-19 overall outweigh the risk of side effects,” she added.
“It is saving lives.”
A number of nations have suspended the use of AstraZeneca’s vaccine for younger populations after it was earlier banned outright in several places over blood clot scares among younger people.
The back-and-forth over the shot comes as countries from Germany to Ukraine and India face new waves of infections and deaths from the virus that has now killed more than 2.8 million people globally.
Governments are scrambling to secure much-needed vaccine doses, with Australia the latest nation to complain of shortages that it blamed on EU export controls.
The European Medicines Agency (EMA) said Wednesday that blood clots were a “very rare” risk, encouraging countries to continue its use.
“EMA’s safety committee has concluded today that unusual blood clots with low blood platelets should be listed as very rare side effects” of the shot, the agency said in a statement.
The announcement came after its safety committee examined reports of blood clots, but EMA chief Emer Cooke said no particular risk factor had been identified but the clots could be linked to an immune response to the vaccine.
“Specific risk factors such as age, gender or medical history have not been able to be confirmed, as the rare events are seen in all ages,” she told a news conference.
“The benefits of the AstraZeneca vaccine in preventing Covid-19 overall outweigh the risk of side effects,” she added.
“It is saving lives.”
